Tirzepatide
Overview
First-in-class twincretin combining GIP and GLP-1 receptor agonism in a single molecule. Studied for glycemic control and substantial weight reduction in clinical trials.
Research profile · for clinicians
Based on research: a metabolic dual agonist studied for combined glycemic control and pronounced weight reduction. The added GIP receptor activity is investigated as a driver of improved insulin sensitivity and additional appetite suppression beyond single-receptor GLP-1 analogues.
Mechanism of action
Concurrent activation of GIP and GLP-1 receptors enhances insulin sensitivity, improves β-cell function, and amplifies satiety signaling beyond mono-agonist analogues.
Research record
- [01]SURPASS program — glycemic outcomes in T2D research literature.
- [02]SURMOUNT program — body-weight outcomes in obesity research.
Selected references
Tirzepatide once weekly in T2D
NEJM, 2021
Tirzepatide for obesity (SURMOUNT-1)
NEJM, 2022